Quarterly report · Q2
4483.TEDINET S100PLQM
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.1bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.3bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥9.6bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥5.0bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥909m | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥908m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥678m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥597m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥677m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥1.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥598m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥112.1bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥58.1bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥50.5bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥61.6bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.9bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥61.6bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥28.9bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥41.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥15.5bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥21.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥48.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥25.29 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.76 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥20.26 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥10.64 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥23.86 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.14 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.06 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥10 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.8% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥189m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥99m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥933m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥890m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥84m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥192m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥144m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥24m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥903m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥924m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥485m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥6.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥6.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥126m |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥67m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥88m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥53m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥88m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥53m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥157m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥82m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥877m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥847m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥56m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥29m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥163m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥113m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥31m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥23m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥877m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥730m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥400m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥9.6bn |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥5.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥9.6bn |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥5.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥88m |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥53m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 883
| Item | Context | Value | Unit |
|---|---|---|---|
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember | 485000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember | 144000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 1533000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -99000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration | 1434000000 | JPY |
| Segment profit loss IFRS | Prior1QuarterDuration | 1308000000 | JPY |
| Segment profit loss IFRS | CurrentQuarterDuration | 1434000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1QuarterDuration | 385000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentQuarterDuration | 491000000 | JPY |
| Other income IFRS | Prior1QuarterDuration | 8000000 | JPY |
| Other income IFRS | CurrentQuarterDuration | 183000000 | JPY |
| Other expenses IFRS | Prior1QuarterDuration | 21000000 | JPY |
| Other expenses IFRS | CurrentQuarterDuration | 0 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration | 909000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration | 1126000000 | JPY |
| Finance income IFRS | Prior1QuarterDuration | 13000000 | JPY |
| Finance income IFRS | CurrentQuarterDuration | 13000000 | JPY |
| Finance costs IFRS | Prior1QuarterDuration | 14000000 | JPY |
| Finance costs IFRS | CurrentQuarterDuration | 26000000 | JPY |
| Profit loss before tax IFRS | Prior1QuarterDuration | 908000000 | JPY |
| Profit loss before tax IFRS | CurrentQuarterDuration | 1113000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-11 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第10期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Company name in english cover page | FilingDateInstant | JMDC Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 兼 ＣＥＯ 松島 陽介 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役副社長 兼 ＣＦＯ 山元 雄太 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役副社長 兼 ＣＦＯ 山元 雄太 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35308 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 44830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Filer name in english | FilingDateInstant | JMDC Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |